X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
abemaciclib (165) 165
palbociclib (118) 118
index medicus (98) 98
oncology (96) 96
breast cancer (94) 94
ribociclib (78) 78
combination (61) 61
fulvestrant (59) 59
humans (51) 51
endocrine therapy (47) 47
cdk4 (40) 40
cyclin-dependent kinase 4 - antagonists & inhibitors (38) 38
therapy (38) 38
cyclin-dependent kinases (37) 37
letrozole (37) 37
cyclin-dependent kinase 6 - antagonists & inhibitors (36) 36
female (36) 36
breast neoplasms - drug therapy (35) 35
cancer (35) 35
metastasis (35) 35
cdk4/6 inhibitors (30) 30
antitumor-activity (26) 26
pd 0332991 (25) 25
phase-i (25) 25
care and treatment (24) 24
dependent kinase 4/6 (24) 24
pharmacology & pharmacy (24) 24
phase-ii (24) 24
cell cycle (23) 23
clinical trials (23) 23
medicine & public health (23) 23
breast-cancer (22) 22
cyclin-dependent kinase 4 (22) 22
double-blind (22) 22
cell-cycle (21) 21
chemotherapy (21) 21
protein kinase inhibitors - therapeutic use (21) 21
women (20) 20
breast neoplasms - pathology (19) 19
cancer therapies (19) 19
erbb-2 protein (19) 19
metastases (19) 19
metastatic breast cancer (19) 19
1st-line treatment (18) 18
patients (18) 18
analysis (17) 17
cdk4/6 inhibitor (17) 17
cyclin-dependent kinase (17) 17
kinases (16) 16
review (16) 16
tumors (16) 16
article (15) 15
cdk6 (15) 15
cell biology (15) 15
protein kinase inhibitors - pharmacology (15) 15
drug therapy (14) 14
endocrine resistance (14) 14
obstetrics & gynecology (14) 14
6 inhibitor (13) 13
6 inhibitors (13) 13
aminopyridines - pharmacology (13) 13
animals (13) 13
cyclin d1 (13) 13
epidermal growth factor (13) 13
postmenopausal women (13) 13
resistance (13) 13
safety (13) 13
medical research (12) 12
toxicity (12) 12
antineoplastic agents - therapeutic use (11) 11
benzimidazoles - pharmacology (11) 11
cyclin-dependent kinase 4 - metabolism (11) 11
expression (11) 11
health aspects (11) 11
medical colleges (11) 11
neoplasms. tumors. oncology. including cancer and carcinogens (11) 11
piperazines - therapeutic use (11) 11
pyridines - therapeutic use (11) 11
survival (11) 11
advanced breast cancer (10) 10
antineoplastic agents - pharmacology (10) 10
antineoplastic combined chemotherapy protocols - therapeutic use (10) 10
breast neoplasms - metabolism (10) 10
cdk4/6 (10) 10
cyclin-dependent kinase 6 - metabolism (10) 10
estrogen (10) 10
inhibitors (10) 10
kinase 4/6 inhibitor (10) 10
piperazines - pharmacology (10) 10
pyridines - pharmacology (10) 10
tamoxifen (10) 10
treatment outcome (10) 10
trial (10) 10
aminopyridines - administration & dosage (9) 9
aminopyridines - therapeutic use (9) 9
antineoplastic agents - administration & dosage (9) 9
antineoplastic agents - adverse effects (9) 9
hormones (9) 9
inhibitor (9) 9
molecular targeted therapy (9) 9
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cancer Discovery, ISSN 2159-8274, 11/2018, Volume 8, Issue 11, pp. 1390 - 1403
CDK4/6 inhibition with endocrine therapy is now a standard of care for advanced estrogen receptor-positive breast cancer. Mechanisms of CDK4/6 inhibitor... 
ONCOLOGY | DNA | ESR1 MUTATIONS | ENDOCRINE THERAPY | ABEMACICLIB | INHIBITORS | TUMORS | PROGRESSION | RB1 | palbociclib | fulvestrant | circulating tumor DNA
Journal Article
Clinical cancer research : an official journal of the American Association for Cancer Research, ISSN 1078-0432, 9/2017, Volume 23, Issue 17, pp. 5218 - 5224
Journal Article
Oncotarget, ISSN 1949-2553, 10/2019, Volume 10, Issue 59
Journal Article
Drug Design, Development and Therapy, 02/2018, Volume 12, pp. 321 - 330
Journal Article
Expert Review of Anticancer Therapy, ISSN 1473-7140, 11/2019, Volume 19, Issue 11, pp. 917 - 919
Journal Article
NATURE COMMUNICATIONS, ISSN 2041-1723, 03/2019, Volume 10
Using an ORF kinome screen in MCF-7 cells treated with the CDK4/6 inhibitor ribociclib plus fulvestrant, we identified FGFR1 as a mechanism of drug resistance.... 
PALBOCICLIB | AMPLIFICATION | THERAPY | MULTIDISCIPLINARY SCIENCES | GROWTH | ACQUIRED-RESISTANCE | MUTATIONS | ABEMACICLIB | PHARMACOLOGICAL INHIBITION | COMBINATION | EXPRESSION
Journal Article
JOURNAL OF CLINICAL ONCOLOGY, ISSN 0732-183X, 05/2019, Volume 37, Issue 14, pp. 1148 - 1148
Journal Article
Cell Reports, ISSN 2211-1247, 03/2018, Volume 22, Issue 11, pp. 2978 - 2994
Abemaciclib, an inhibitor of cyclin dependent kinases 4 and 6 (CDK4/6), has recently been approved for the treatment of hormone receptor-positive breast... 
PD-L1 | combination immunotherapy | cancer | CDK4/6 | PD-1 | abemaciclib | BREAST-CANCER | IMMUNITY | PALBOCICLIB | THERAPY | CDK6 | SENESCENCE | ANTITUMOR-ACTIVITY | CELL BIOLOGY
Journal Article
Cancer Discovery, ISSN 2159-8274, 04/2016, Volume 6, Issue 4, pp. 353 - 367
Journal Article
Molecular cancer therapeutics, ISSN 1535-7163, 02/2019, Volume 18, Issue 2, pp. 257 - 266
Recently three different cyclin-dependent kinase 4 and 6 (CDK4/6) dual inhibitors were approved for the treatment of breast cancer (palbociclib, ribociclib,... 
BREAST-CANCER | PALBOCICLIB | STEM-CELLS | THERAPY | ONCOLOGY | WNT/BETA-CATENIN | LETROZOLE | DIFFERENTIATION | TIDEGLUSIB | ABEMACICLIB | COMBINATION
Journal Article
NATURE REVIEWS CLINICAL ONCOLOGY, ISSN 1759-4774, 02/2018, Volume 15, Issue 2, pp. 79 - 80
Data published in 2017 underscore the benefit of optimizing anti-HER2 therapy in early stage high-risk HER2-positive disease, and of capecitabine in patients... 
TRIAL | PALBOCICLIB | TRASTUZUMAB | ONCOLOGY | FULVESTRANT | METASTATIC BREAST-CANCER | DOUBLE-BLIND | ENDOCRINE THERAPY | ABEMACICLIB
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2018, Volume 379, Issue 20, pp. 1926 - 1936
Journal Article
Oncotarget, ISSN 1949-2553, 02/2019, Volume 10, Issue 12, pp. 1230 - 1232
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 08/2018, Volume 24, Issue 16, pp. 3994 - 4005
Purpose: To characterize the ionizing radiation (IR) enhancing effects and underlying mechanisms of the CDK4/6 inhibitor abemaciclib in non-small cell lung... 
BREAST-CANCER | GROWTH-FACTOR RECEPTOR | GLIOBLASTOMA | ANGIOGENESIS | ONCOLOGY | VASCULOGENESIS | SENSITIVITY | MUTATIONS | DEPENDENT KINASE INHIBITOR | MTOR | EGFR | Abemaciclib | Radiosensitizer | Vasculogenesis | Metabolism | CDK4 | Cell Cycle NSCLC
Journal Article
Oncotarget, ISSN 1949-2553, 2017, Volume 8, Issue 41, pp. 69493 - 69507
Abemaciclib is an ATP-competitive, reversible kinase inhibitor selective for CDK4 and CDK6 that has shown antitumor activity as a single agent in hormone... 
Abemaciclib | Senescence | Cell cycle | Hormone receptor positive breast cancer | Apoptosis | cell cycle | CYCLIN D1 | PHOSPHORYLATION | abemaciclib | SENSITIVITY | apoptosis | CELL BIOLOGY | senescence | CDK4 | hormone receptor positive breast cancer | CELL-CYCLE | INHIBITOR | REQUIREMENT
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.